This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bedi, A. Articles by Jones, R. J. Search for Related Content PubMed PubMed Citation Articles by Bedi, A. Articles by Jones, R. J.

Growth Factor-mediated Terminal Differentiation of Chronic Myeloid Leukemia¹

Johns Hopkins Oncology Center, Baltimore, Maryland 21287-8967

Expression of the BCR-ABL chimeric gene in chronic myeloid leukemia results in the inhibition of apoptosis, a genetically programmed process of autonomous cell death. BCR-ABL and other genetic factors that suppress apoptosis confer cross-resistance to cytotoxic agents with diverse mechanisms of action. Eradication of the chronic myeloid leukemia clone requires strategies that circumvent this inherent resistance to cytotoxic therapy. We have determined that BCR-ABL expression augments the sensitivity of hematopoietic cells to growth factor-mediated signals of differentiation; hematopoietic growth factors induce the selective terminal differentiation of chronic myeloid leukemia progenitors at concentrations that allow optimal growth of normal progenitors. Hematopoietic growth factors may be an effective strategy for the elimination of cytotoxic therapy-resistant leukemic cells by inducing their terminal differentiation while allowing concomitant expansion of coexistent normal hematopoietic progenitors.

¹ Supported in part by Grants CA15396 and HL46533 from the NIH. R. J. J. is a Leukemia Society of America Scholar.

² To whom requests for reprints should be addressed, at Room 2-127, The Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD 21287-8967.

Received 8/22/94. Accepted 9/20/94.

This article has been cited by other articles:

				D. H. Kim, W. Xu, C. Ma, X. Liu, K. Siminovitch, H. A. Messner, and J. H. Lipton Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia Blood, March 12, 2009; 113(11): 2517 - 2525. [Abstract] [Full Text] [PDF]

				P. Ramaraj, H. Singh, N. Niu, S. Chu, M. Holtz, J. K. Yee, and R. Bhatia Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors Cancer Res., August 1, 2004; 64(15): 5322 - 5331. [Abstract] [Full Text] [PDF]

				W. H. Matsui, D. E. Gladstone, M. S. Vala, J. P. Barber, R. A. Brodsky, B. D. Smith, and R. J. Jones The Role of Growth Factors in the Activity of Pharmacological Differentiation Agents Cell Growth Differ., June 1, 2002; 13(6): 275 - 283. [Abstract] [Full Text] [PDF]

				M. S. Holtz, M. L. Slovak, F. Zhang, C. L. Sawyers, S. J. Forman, and R. Bhatia Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation Blood, May 15, 2002; 99(10): 3792 - 3800. [Abstract] [Full Text] [PDF]

				M. H. Tomasson, I. R. Williams, S. Li, J. Kutok, D. Cain, S. Gillessen, G. Dranoff, R. A. Van Etten, and D. G. Gilliland Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3 Blood, March 1, 2001; 97(5): 1435 - 1441. [Abstract] [Full Text] [PDF]

				N. C. Gorin, E. Estey, R. J. Jones, H. I. Levitsky, I. Borrello, and S. Slavin New Developments in the Therapy of Acute Myelocytic Leukemia Hematology, January 1, 2000; 2000(1): 69 - 89. [Abstract] [Full Text] [PDF]